Navlimetostat (Standard)
Navlimetostat (Standard) is the analytical standard of Navlimetostat (HY-139611). This product is intended for research and analytical applications. Navlimetostat is a potent, orally active, selective PRMT5-MTA complex inhibitor, with IC50 of 3.6 and 20.5 nM for PRMT5-MTA and PRMT5. Navlimetostat binds to the PRMT5-MTA complex, with Kd value of 0.14 pM. Navlimetostat shows antineoplastic activity in vitro and in vivo, and can be used for cancer study.
For research use only. We do not sell to patients.
- CAS No.: 2630904-45-7
- Formula: C23H18ClFN6O2
- Molecular Weight:464.88
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Product Information
Information
Application
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
CAS No. 2630904-45-7
-
Molecular Weight 464.88
-
Formula C23H18ClFN6O2
-
SMILES
FC1=C(C=C(C(C#N)=[C@]1[C@]2=C(C3=CC=C4C(C(CN)=NNC4=O)=C3)C=NN2C)OC5CC5)Cl
-
Synonyms
MRTX-1719 (Standard); BMS-986504 (Standard)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Lars D Engstrom, et al. MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer. Cancer Discov. 2023 Aug 8;CD-23-0669. [Content Brief]
[2]. Christopher R Smith, et al. Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of MTAP-Deleted Cancers. J Med Chem. 2022 Feb 10;65(3):1749-1766. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)